Medical Condition News

RSS

Exelixis announces preliminary results from BRIM7 Phase Ib trial on BRAFV600 mutated MM

Exelixis, Inc. today announced preliminary results from BRIM7, an ongoing Phase Ib trial conducted by Roche and Genentech, Exelixis' collaborator and a member of the Roche Group, of the BRAF inhibitor (BRAFi) vemurafenib in combination with the MEK inhibitor GDC-0973 in patients with locally advanced/unresectable or metastatic melanoma carrying a BRAFV600 mutation.

29 Sep 2012

New trial data shows improvements in treatment of esophageal and gastrointestinal cancers

New trial data showing improvements in the treatment of esophageal and gastrointestinal cancers were released today at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

29 Sep 2012

JAAD to publish Sensus Healthcare’s superficial radiotherapy study on non melanoma skin cancer

Sensus Healthcare is pleased to announce the acceptance and publication of the most comprehensive study to date on treating Non Melanoma Skin Cancer (NMSC) with superficial radiotherapy (SRT) in the Journal of the American Academy of Dermatology (JAAD).

29 Sep 2012

PLOS ONE journal releases report on validation of Falcon Genomics' Cancer BioChip System

The online journal PLOS ONE released a scientific report on the validation of Falcon Genomics' Cancer BioChip System (CBCS) as a tool for identifying inhibitors of breast cancer.

29 Sep 2012

Cardiac Dimensions commences commercialization of CARILLON mitral contour system in Europe

Cardiac Dimensions, Inc. today announced that it has initiated its commercial efforts in Europe, treating the first patients with its CARILLON Mitral Contour System under its Conformite Europeenne (CE) Mark approval.

29 Sep 2012

Intarcia announces results from ITCA 650 phase 2 study on type 2 diabetes

Intarcia Therapeutics, Inc. announced that an analysis of the results of a phase 2 clinical study of ITCA 650 (continuous subcutaneous delivery of exenatide) for the treatment of type 2 diabetes will be presented at the 48th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Berlin, Germany on Wednesday, October 3, 2012.

29 Sep 2012

FDA approves Stiefel’s Sorilux Foam sNDA to treat for scalp psoriasis

Stiefel, a GSK company, today announced that the US Food and Drug Administration has approved a supplemental New Drug Application (sNDA) for Sorilux (calcipotriene) Foam, 0.005%. The sNDA expands the indication for Sorilux Foam to include the topical treatment of plaque psoriasis of the scalp in patients aged 18 years and older.

29 Sep 2012

Rapamycin can alleviate frontotemporal lobar degeneration

A southern Taiwan-based National Cheng Kung University (NCKU) research team has discovered that rapamycin, a drug as a autophagy activator is a possible treatment to alleviating frontotemporal lobar degeneration (FTLD), one of the mainly causes of dementia, and so far no medication can be used.

29 Sep 2012

Seattle conference to focus on trauma and addiction treatment

The incidence of trauma and abuse has truly reached epidemic proportions, and those who suffer trauma sometimes turn to alcohol or other drugs to manage post-traumatic stress symptoms like nightmares, anxiety, insomnia, and dissociation.

29 Sep 2012

FDA approves Boston Scientific’s S-ICD system to treat sudden cardiac arrest

The U.S. Food and Drug Administration has granted Boston Scientific Corporation regulatory approval for its S-ICD System, the world's first and only commercially available subcutaneous implantable defibrillator (S-ICD) for the treatment of patients at risk for sudden cardiac arrest (SCA).

29 Sep 2012

GCE group, Dehaier partner to distribute EASE II products in China

Dehaier Medical Systems Ltd., an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China, today announced that it has signed a two-year distribution agreement with GCE group, a leading global compressed gas-equipment company, to become the exclusive distributor for GCE's EASE II products in Mainland China.

29 Sep 2012

New research on addiction mutual-support groups

Mutual-help groups for addiction have proliferated, diversified, and adapted to emerging substance-related trends over the past 75 years. A new special, triple issue of the Journal of Groups in Addiction & Recovery - Broadening the Base of Addiction Mutual Support: Bringing Theory and Science to Contemporary Trends - reviews the history of mutual-support groups for addiction that have arisen as adjuncts or alternatives to Twelve Step Programs.

29 Sep 2012

AVEO submits tivozanib NDA with FDA for treatment of advanced renal cell carcinoma

AVEO Oncology and Astellas Pharma Inc. today announced that AVEO has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for tivozanib in patients with advanced renal cell carcinoma (RCC).

29 Sep 2012

FDA approves Abbott’s HUMIRA to treat ulcerative colitis

Abbott today announced that the U.S. Food and Drug Administration (FDA) has approved HUMIRA (adalimumab) for inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis (UC) when certain other medicines have not worked well enough.

29 Sep 2012

1-800-Oncologist launches Contributing Expert program

1-800-Oncologist, Inc. announced today the launch of its Contributing Expert program for oncology and radiology specialists. Members of 1-800-Oncologist's national Contributing Expert network are key opinion leaders in the cancer field that help translate medical news into information patients can understand and act upon.

29 Sep 2012

Cameron Health receives FDA approval for subcutaneous implantable defibrillator system

The U.S. Food and Drug Administration today approved a heart defibrillator that helps to restore regular heart rhythms with leads that can be implanted just under the skin (subcutaneously) instead of connected directly into the heart.

29 Sep 2012

FDA approves Globus Medical’s SECURE-C Cervical Artificial Disc

Globus Medical, Inc., today announced that the Food and Drug Administration (FDA) has granted Premarket Approval (PMA) for the SECURE-C Cervical Artificial Disc. Clinical data from a 380 patient investigational device exemption (IDE) study demonstrate that SECURE-C is statistically superior to anterior cervical discectomy and fusion (ACDF) in terms of overall success, subsequent surgery at the index level, device-related adverse events, and patient satisfaction at 24 months.

29 Sep 2012

A.P. Pharma resubmits APF530 NDA with FDA for prevention of CINV

A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead product candidate, APF530, for the prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV).

29 Sep 2012

Abbott receives FDA approval for Humira to treat ulcerative colitis

The U.S. Food and Drug Administration today expanded the approved use of Humira (adalimumab) to include treatment of moderate-to-severe ulcerative colitis in adults.

29 Sep 2012

Research roundup: Saving money with hospital observation units, total knee replacement rates skyrocketing, Medicare patients and antibiotic overuse

The authors write: Using observation units in hospitals to provide care to certain patients can be more efficient than admitting them to the hospital and can result in shorter lengths-of-stay and lower costs. However, such units are present in only about one-third of US hospitals.

29 Sep 2012

Medical Condition News

Exelixis announces preliminary results from BRIM7 Phase Ib trial on BRAFV600 mutated MM

New trial data shows improvements in treatment of esophageal and gastrointestinal cancers

JAAD to publish Sensus Healthcare’s superficial radiotherapy study on non melanoma skin cancer

PLOS ONE journal releases report on validation of Falcon Genomics' Cancer BioChip System

Cardiac Dimensions commences commercialization of CARILLON mitral contour system in Europe

Intarcia announces results from ITCA 650 phase 2 study on type 2 diabetes

FDA approves Stiefel’s Sorilux Foam sNDA to treat for scalp psoriasis

Rapamycin can alleviate frontotemporal lobar degeneration

Seattle conference to focus on trauma and addiction treatment

FDA approves Boston Scientific’s S-ICD system to treat sudden cardiac arrest

GCE group, Dehaier partner to distribute EASE II products in China

New research on addiction mutual-support groups

AVEO submits tivozanib NDA with FDA for treatment of advanced renal cell carcinoma

FDA approves Abbott’s HUMIRA to treat ulcerative colitis

1-800-Oncologist launches Contributing Expert program

Cameron Health receives FDA approval for subcutaneous implantable defibrillator system

FDA approves Globus Medical’s SECURE-C Cervical Artificial Disc

A.P. Pharma resubmits APF530 NDA with FDA for prevention of CINV

Abbott receives FDA approval for Humira to treat ulcerative colitis

Research roundup: Saving money with hospital observation units, total knee replacement rates skyrocketing, Medicare patients and antibiotic overuse

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News